CHZHAN Yulyan (US),ЧЖАН Юлянь (US),KHODAUS Brajan L. (US),ХОДАУС Брайан Л. (US),KIM Dzhozef L. (US),КИМ Джозеф Л. (US),UILSON Kevin Dzh. (US),УИЛСОН Кевин Дж. (US),UILSON Duglas (US),УИЛСОН Дуглас (US
申请号：
RU2016118768
公开号：
RU0002706235C2
申请日:
2014.10.15
申请国别(地区):
RU
年份:
2019
代理人:
摘要：
FIELD: chemistry； pharmaceutics.SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof. In formula IW is selected from hydrogen and , where Ring A is selected from phenyl or 6-member monocyclic heteroaryl with one ring heteroatom selected from N； each X and Y is independently selected from CR1 and N； Z is selected from phenyl, 5- or 6-membered monocyclic heteroaryl with 1–2 ring heteroatoms independently selected from N, O and S, 6-membered monocyclic partially unsaturated heterocyclyl with one ring heteroatom selected from N； where each of phenyl, monocyclic heteroaryl and monocyclic heterocyclyl is independently substituted with 0–2 groups RC； L is selected from bond, -(C(R2)(R2))m-, -(C2-C6 alkynylene)-, -O-, -S- and -S(O)2-； each RA and RB is independently selected from halogen, C1-C6 alkyl and C1-C6 hydroxyalkyl； each RC is independently selected from C1-C6 alkyl, C1-C6 alkoxy, halogen, C1-C6 hydroxyalkyl, C3-C7 cycloalkyl, 4-member heterocyclyl with one ring heteroatom selected from O, (6-member heterocyclyl with 2 ring heteroatoms selected from N, O)-C1-C6 alkyl, cyano, -C(O)OR2 and -C(O)-N(R2)(R2)； each RD and RF is independently selected from hydrogen and -N (R2) (R2)； each R1 is hydrogen； each R2 is independently selected from hydrogen, hydroxyl, -NR "R", C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C7 cycloalkyl, or 2 R2 together with atoms, to which they are bonded, form 4-member heterocyclyl ring with 1 ring atom selected from O； each R "is hydrogen or C1-C6 alkyl； and m, p and q – each independently represent 0, 1, 2, 3 or 4. Invention also relates to individual compounds, to a pharmaceutical composition, to methods of treatment.I.EFFECT: technical result is obtaining novel compounds of formula I, having modulating activity on KIT and/or PDGFRα.25 cl, 2 dwg, 3 tbl, 7 exИзобретение относится к соединению Формулы I или к его фармацевтически приемлемой соли. В формуле I W выбран из водор
